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2High Throughput Synthesis of Diverse 2,5-Disubstituted Indoles using Titanium Carbenoids
Bearing Boronate Functionality
Calver A. Main,a Hanna M. Petersson,a  Shahzad S. Rahmanb and Richard C. Hartley.a
aWestCHEM Department of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK
bGlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW
Abstract – A titanium benzylidene complex bearing a boronate group converted resin-bound esters
into enol ethers.  Suzuki cross-coupling with aryl iodides, followed by cleavage with acid
completed the solid-phase synthesis of 2,5-disubstituted N-Boc-indoles.  Also reported is the use of
tertiary butyllithium and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane to convert an aryl
bromide into an aryl boronate in the presence of a dithiane, with simultaneous reduction of an aryl
azide to an amine.
Introduction
The discovery of new lead compounds can be achieved through the synthesis of a large
numbers of compounds in parallel, constituting a compound library, followed by high throughput
screening.1 The members of the library should be diverse in structure so as to effectively probe
chemical space, but because chemical space is so large, the inclusion of structural features that are
often associated with biological activity, known as "privileged structures",2,3 improves the chances
of obtaining a useful lead compound.  Once a lead is established, focussed libraries can then be
prepared, which may well contain a range of privileged structures.  The use of solid-phase synthesis
facilitates the preparation of the libraries as it allows automation.4
Recently, we have developed functionalised titanium carbenoids5 to prepare benzofurans
2,6,7 indoles 3,7 benzothiophenes 4,8 quinolines 5,9 cyclic imines10,11 6 and enantiomerically enriched
piperidines11 7 and 8 from resin-bound esters 1, so that each ester acts as a precursor to a range of
privileged structures (Scheme 1). The general strategy involves using titanium carbenoids 9
containing a masked nucleophile to convert acid-stable, resin-bound esters 1 into acid-sensitive enol
ethers 10 (Scheme 2). Treatment with mild acid leads to cleavage from resin with concomitant
cyclisation to generate bicyclic heteroaromatic compounds 11 with no trace of the site of
attachment to resin. The switch to a linker cleaved under orthogonal conditions ensures that any
unreacted ester 1 remains attached to the resin and so the products 11 are released in high purity.
Barrett and co-workers introduced the term "chameleon catch" to describe this switch in the nature
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3of a linker.12,13  In theory, it allows greater diversity to arise from each resin-bound ester 1 as other
products would be available from cleaving at the ester stage (e.g. carboxylic acids, alcohols etc.).
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One limitation of our original strategy was that no additional diversity was added after the
switch of the linker, and we overcame this in the benzofuran series by including a boronate group in
the titanium reagent 12.14  Suzuki cross-coupling between boronate 13 and a variety of aryl iodides
then allowed access to a range of ketones 14 that cyclised upon deprotection in strong acid to give
2,5-disubstituted benzofurans 15. Aryl bromides react under the conditions used to generate our
titanium benzylidene reagents 9, precluding the introduction of aryl bromide or iodide functionality
to the resin by our method.7  However, immobilisation of the arylboronate component is
advantageous as aryl halides are more widely and cheaply available than arylboronates.  Therefore,
it is surprising that the aryl halide is almost always the immobilised coupling partner for cross
couplings in SPS.15
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We here report a similar strategy for introducing diversity in the indole series.  The indole
moiety is the archetypal privileged structure, and alkaloids derived from the indole-containing
amino acid, tryptophan, are found widely in nature.16  These include the human 5-
hydroxytryptamine (5-HT) hormones, serotonin, which is involved in regulation of the nervous
system including neurotransmission, and melatonin, which regulates circadian rhythms and sleep
processes.  Although, natural indoles are almost invariably 3-substituted, 2-substituted analogues of
these hormones are also being investigated as potential therapeutic agents.17  Other bioactive 2-
substituted indoles recently reported include inhibitors of the proteases involved in coagulation e.g.
factor VIIa inhibitors,18 antagonists of G-protein-coupled receptors,19 anti-angiogenic compounds20
and inhibitors of endothelin-converting-enzyme.21 Naturally, new methods for the construction and
modification of indole moieties during SPS are continually being reported.22,23  However, the
combination of intermolecular alkylidenation of an ester group followed by cyclisation to give an
indole is unique to us.
Results and Discussion
We chose 5-bromo-2-fluorobenzaldehyde 16 as the starting material for the synthesis of titanium
benzylidene complexes, as we reasoned that an amino group could be introduced through SNAr
displacement of the fluoride by a suitable nucleophile, the bromide could be replaced by boron
5through cross-coupling and the aldehyde would easily be converted into a dithiane.  Displacement
of fluoride by azide proceeded smoothly to give aldehyde 17, which was then converted into
dithiane 18.  Reduction of the azide gave aniline derivative 19. This was converted into carbamate
20, which was benzylated to give aryl bromide 21 .  Miyaura cross-coupling then introduced the
boronate in high yield, completing the synthesis of a dithiane 22.24  Treating the dithiane 22 with
freshly prepared Takeda reagent,25 Cp2Ti[P(OEt)3]2, gave a titanium carbenoid, presumed to be
titanium benzylidene 23.  This was used immediately without isolation to benzylidenate resin-
bound ester 24, prepared from Merrifield resin and contained within MacroKansTM, which are small
porous polypropylene reactors (0.315 meq. of resin per reactor, using of resin with a loading of 1.97
meq. g-1) that allow easy handling of the resin in normal glassware.  Cleavage of the resulting resin-
bound enol ether 25 with acid and cyclisation under our published conditions then gave boronate
26.26  Alternatively, Suzuki cross-coupling between the resin-bound arylboronate 25 and aryl
iodides to give enol ethers 27, under conditions optimised previously,14 followed by release and
cyclisation gave N-benzyl indoles 28, 29 and 30.  Yields are based on the original loading of the
Merrifield resin and so are over 5 steps. The products were isolated in high purity without the need
for chromatography.
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Scheme 5 Yields based on original loading of Merrifield resin
While N-benzyl indoles can be deprotected to give indoles,27 N-Boc protecting groups are
more easily removed.28  Unfortunately, Miyara cross-coupling had failed when amine 19 or primary
carbamate 20 were the substrate.29  Presumably, coordination of palladium by the dithiane poisons
the catalyst, and this coordination is prevented by the bulky N-benzyl carbamate.  In addition to this
limitation, we considered that the Miyaura cross-coupling was expensive, even if a cheaper
catalysts is used,30 due to the cost of bis(pinacolato)diboron.  Consequently, it seemed better to
introduce the boron by lithiation and trapping with a borate ester.  Under optimised conditions,
treatment of aryl bromide 18 with 3.1 eq. of tert-butyllithium and quenching with borate 33 gave
amine 34 after crystallisation.  In spite of the modest yield, the 1H NMR spectrum of the crude
mixture following work up appeared to contain no other aromatic compounds.  2 of the 3 eq. of
tert.-butyllithium are required to convert the aryl bromide moiety into an aryllithium and to destroy
the resulting tert-butyl bromide.31  Organolithiums are known to attack the terminal nitrogen of aryl
azides and alkyl azides to give 1-aryl-3-alkyltriazenes and 1,3-dialkyltriazenes, respectively,32 so
dilithiated triazenes 31 and 32 are likely to be intermediates.  1-Aryl-3-alkyltriazenes decompose in
acid to the corresponding anilines with loss of nitrogen and generation of an alkyl carbocation, and
the reaction is particularly fast when the carbocation is stabilised.33  A similar decomposition
appears to be induced by the borate 33.   Interestingly, 1,3-disubstituted triazenes have been used as
electrophile-cleavable linkers in solid-phase synthesis, but trisubstituted triazenes are much more
versatile and popular.34  Although the reaction of allyl azide with aryllithiums, followed by acid-
induced decomposition, is a known method for preparing anilines,35 the generation of anilines from
aryl azides using tert-butyllithium is new.
Boc protection of amine 34 gave carbamate 35, which was then silylated to give a suitable
substrate 36 for the generation of a titanium benzylidene 37 under Takeda conditions.  Again, once
8generated, the titanium reagent was used immediately to benzylidenate resin-bound ester 24, and
cleavage with concomitant cyclisation was achieved under mild conditions7,36 to give the N-Boc
indole 39.  Suzuki cross-couplings between the intermediate boronate 38 and a variety of aryl and
heteroaryl iodides gave enol ethers led to the production of 2,5-substituted indoles 40-43 in good
purity without the need for chromatography.  However, cross-coupling with 1-iodo-4-nitrobenzene
conditions gave a 5:1 mixture of the expected product 44 and a compound 45, presumably arising
from Buchwald coupling,37,38 which could not be avoided.
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With good conditions in hand for the alkylidenation, cross-coupling, cleavage sequence, we
decided to prepare a library of 96 indoles 49 (Scheme 8), using smaller amounts of resin in
MiniKansTM, which are smaller porous polypropylene reactors (93 meq. of resin per MiniKanTM,
using Merrifield resin with a loading of 2.0 meq. g-1).  8 resin-bound esters 46 were prepared and for
each ester, 13 MiniKansTM containing the same resin-bound ester were alkylidenated together to
give enol ethers 47.  One MiniKanTM from each batch was subjected to the cleavage conditions to
give the boronates 48 in good yield and purity, with the exception of 48H, which was very impure.
The identity of the boronate products 48 was confirmed by 1H NMR spectroscopy of the crude
material from cleavage following evaporation of solvent. Enol ether 47G, which has two N-Boc
groups, yielded a mono-Boc compound 48G'.  It is believed that the N-Boc on the indole is
retained, based on the chemical shift of the tert-butyl group, and the obvious stability of the other
N-Boc indoles 48A-F.  It is noteworthy that indoles containing Lewis basic sites (48D-G') could be
made using reagent 37, but it would appear that the 1,2,4-oxadiazole unit has limited stability to the
reaction conditions.
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12 batches of the 8 resin-bound enol ethers 47A-H contained in MiniKansTM were each
subjected to Suzuki cross-coupling with a different aryl or heteroaryl iodide, followed by cleavage
from resin in separate vessels to give indoles 49.  The crude yields and purities are presented in
Table 1. The library members were identified using reversed phase HPLC, with diode array UV
detection (DAD-UV) and evaporative light scattering detection (ELSD) and MS analysis. The
purity values for the library members were determined using summed diode array UV detection
(DAD-UV) between the wavelengths of 210 nm and 350 nm. In 13 examples (in bold), the identity
of the library members were further confirmed by 1H NMR spectroscopy following purification by
reversed phase HPLC. It is noteworthy that even when the yield and purity were low, as was the
case for indole 49Fh, sufficient material could be obtained for identification in this way, giving
confidence that other compounds in the library were correctly identified by reversed phase
11
HPLC/DAD-UV/ELSD/MS.  Thus, in 79 cases the desired indole was produced (82% success).
Surprisingly, di-Boc compounds 49G were produced, and deprotection of the aliphatic amino group
did not dominate. As would be expected from the poor quality of boronate 48H, there were few
products arising from enol ether 47H. The enol ethers 47 had efficiently cross coupled with a wide
range of aryl and heteroaryl iodides including both electron-rich substrates a-c and electron-poor
substrates i-l. It is not clear why some derivatives of 3-iodothiophene were not formed, but 3-
iodopyrazole39 g appears to be a poor substrate for Suzuki cross coupling.  Indeed, there are no
reports of palladium-catalysed cross couplings with this substrate in the literature.
Table 1
Yields of indoles 49 synthesised (unpurified material, purities in parenthesis)
A B C D E F G H
a 66 (89) 72 (97) 78 (81) 53 (70) 64 (88) 72 (94) 68 (71) *
b 62 (69) 55 (77) 35 (78) 61 (84) 67 (47) 74 (70) 59 (60) *
c 53 (79) 48 (80) 37 (83) 56 (69) 57 (77) 37 (43) 46 (16) *
d * * 56 (54) 63 (44) 65 (50) 80 (46) * *
e 60 (66) 62 (91) 30 (73) 72 (87) 64 (29) 35 (32) 39 (24) *
f 65 (41) 76 (8) 65 (39) 60 (64) 43 (27) 30 (35) 39 (18) *
g 57 (36) * * * 92 (33) 89 (21) 71 (20) *
h 50 (70) 73 (64) 41 (59) 65 (100) 52 (48) 41 (13) 57 (43) 39 (84)
i 58 (21) 49 (55) 48 (15) 62 (41) 59 (18) 40 (35) * 18 (12)
j 85 (64) 69 (57) 41 (61) 57 (55) 60 (51) 38 (67) 34 (63) *
k 81 (86) 62 (91) 78 (71) 90 (75) 89 (78) 68 (77) 67 (84) *
l 45 (91) 74 (91) 51 (94) 76 (86) 64 (64) 48 (70) 42 (13) *
 * MW of product not detected
Conclusion
In summary, we have synthesised new titanium carbenoid reagents bearing a boronate
functionality, using a sequence that involved a novel reduction of an aryl azide with tert-
butyllithium.  We have demonstrated that this organotitanium reagent can be used for the SPS
synthesis of 2,5-disubstituted indoles, and we have exemplified the benzylidenation, Suzuki cross
coupling, cleavage-cyclisation sequence for introducing diversity by successfully preparing 79 of
the members of a potential 96-member library of indoles.
Experimental
12
1H and 13C NMR spectra were obtained on a Bruker DPX/400 spectrometer operating at 400 and
100 MHz respectively. All coupling constants are measured in Hz and are uncorrected. DEPT was
used to assign the signals in the 13C NMR spectra as C, CH, CH2 or CH3.  Mass spectra (MS) were
recorded on a Jeol JMS700 (MStation) spectrometer. Infra-red (IR) spectra were obtained on a
Perkin-Elmer 983 spectrophotometer.  A Golden GateTM attachment that uses a type IIa diamond as
a single reflection element was used so that the IR spectrum of each compound (solid or liquid)
could be directly detected without any sample preparation.  Column chromatography was carried
out on silica gel, 70-230 mesh, or neutral alumina (Brockmann grade III). Tetrahydrofuran and
diethyl ether were dried over sodium and benzophenone, and dichloromethane was dried over
calcium hydride.  The solid-phase syntheses were carried out using resin derived from
commercially available Merrifield resin with the loadings described in the text below and contained
in IRORI MacroKansTM (porous polypropylene reactors with an internal volume 2.4 mL, and a pore
size of 74 µm) and IRORI MiniKansTM (porous polypropylene reactors with an internal volume 660
µL, and a pore size of 74 µm).
2-Azido-5-bromobenzaldehyde 17.  Sodium azide (6.71 g, 103 mmol, 2 eq.) was added to a
stirring solution of 5-bromo-2-flourobenzaldehyde 16 (10.5 g, 51.6 mmol, 1 eq.) in DMSO (100
mL) under argon. Reaction mixture was stirred at 50 °C for 6 h.  The reaction mixture was then
poured into ice water, acidified with concentrated HCl. It was then extracted with DCM (2×),
washed with water (2×), dried (MgSO4) and concentrated to give 2-azido 5-bromobenzaldehyde 17
as a yellow solid (10.1 g, 44.8 mmol, 87%); mp: 87-90 °C (yellow needles from iPrOH). Rf[SiO2,
hexane-DCM (2:1)]: 0.58. υmax(Golden Gate)/cm-1:  1670 (CHO), 2129 (N3), 2759 (CH stretch),
2877 (CH stretch). δH (400 MHz, CDCl3): 7.17 (1H, d, J 8.6 Hz, H-3), 7.71 (1H, dd, J 2.4 and 8.6
Hz, H-4), 7.98 (1H, d, J 2.4 Hz, H-6), 10.28 (1H, s, CHO). δC (100 MHz, CDCl3): 118.25 (C),
120.75 (CH), 127.94 (C), 131.62 (CH), 137.98 (CH), 141.85 (C), 187.07 (CH). m/z (EI): 227
[M+•(81Br), 6%], 225 [M+•(79Br), 6], 199 [M+•(81Br) – N2, 27], 197 [M+•(79Br) – N2, 27], 83 (100).
HRMS: 226.9513 and 224.9541. C7H4O81BrN3 requires 226.9518, [M+•(79Br)], and C7H4O79BrN3
requires 224.9538.
2-(2'-Azido-5'-bromophenyl)-1,3-dithiane 18.  1,3-Propanedithiol (6.0 mL, 51 mmol, 1.2 eq.) was
added to a solution of 2-azido-5-bromo-benzaldehyde 17 (10.0 g, 44.5 mmol, 1 eq.) and BF3.OEt2
(7.0 mL, 55 mmol, 1.2 eq.) in dry toluene (100 mL) under an atmosphere of argon. The reaction
mixture was stirred for 2 h. The reaction was then quenched by adding water and was extracted into
DCM (2×). Combined organics were washed with 1 M NaOH (2×), water (2×), dried (MgSO4) and
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concentrated to give 2-(2'-azido-5'-bromoophenyl)-1,3-dithiane 18 (12.8 g, 40.3 mmol, 91%). A
small sample was recrystallised from isopropanol to give dithiane 18 as yellow needles; mp 162-
164 oC. Rf[SiO2, hexane-DCM (2:1)]: 0.74. υmax(Golden Gate)/cm-1:  2093 cm-1 (N3), 2135 (N3),
2898 (CH stretch). δH (400 MHz, CDCl3): 1.86-1.97 (1H, m, Hax-5), 2.14-2.21 (1H, m, Heq-5), 2.91
(2H, dt, J 4.1 and 13.7 Hz, Heq-4 and Heq-6), 3.09 (2H, dt, J 2.4 and 13.5 Hz, Hax-4 and Hax-6), 5.43
(1H, s, H-2), 7.00 (1H, d, J 8.5 Hz, H-3'), 7.43 (1H, dd, J 2.3 and 8.5 Hz, H-4'), 7.74 (1H, d, J 2.3
Hz, H-6'). δC (100 MHz, CDCl3): 24.95 (CH2), 32.13 (CH2), 44.29 (CH), 118.18 (C), 119.25 (CH),
132.08 (C), 132.48 (CH), 132.63 (CH), 135.99 (C). m/z (EI): 317 [M+•(81Br), 20%], 315 [M+•(79Br),
20], 215 [M+•(81Br) – N2 and CH2CHCH2SH, 30], 213 [M+•(79Br) – N2 and CH2CHCH2SH, 30], 83
(100). HRMS: 316.9484 and 314.9503. C10H10 81BrN3S2 requires 316.9478, and C10H1079BrN3S2
requires 314.9500. Microanalysis: C, 38.05; H, 3.13; N, 13.08%. C10H10BrN3S2 requires C, 37.98;
H, 3.19; N, 13.29%.
2-(2'-Amino-5'-bromophenyl)-1,3-dithiane 19.  2-(2'-Azido-5'-bromophenyl)-1,3-dithiane 18
(9.46 g, 29.9 mmol, 1 eq.) dissolved into dry THF (150 mL) was added drop-wise to a stirred
suspension of LiAlH4 (1.70 g, 44.9 mmol, 1.5 eq.) in dry THF (100 mL) under argon and the
mixture was then stirred at rt for 2.5 h.  Saturated aqueous NH4Cl was added carefully under argon
to quench the excess LiAlH4. The reaction mixture was then extracted into Et2O (2×), washed with
water (2×), dried (MgSO4) and concentrated to give amine 459 as a yellow oil (7.99 g, 27.5 mmol,
92%); Rf[SiO2, hexane-DCM (2:1)]: 0.32. υmax(Golden Gate)/cm-1:   1618 (NH2 bend), 2898 (CH
stretch), 2931 (CH stretch), 3353 (NH stretch), 3443 (NH strech). δH (400 MHz, CDCl3): 1.72-1.84
(1H, m, Hax-5), 2.01-2.08 (1H, m, Heq-5), 2.80 (2H, dt, J 4.0 and 13.7 Hz, Heq-4 and Heq-6), 2.94
(2H, dt, J 2.4 and 13.5 Hz, Hax-4 and Hax-6), 4.09 (2H, s, NH2), 5.11 (1H, s, H-2), 6.45 (1H, d, J 8.5
Hz, H-3'), 7.09 (1H, dd, J 2.3 and 8.5 Hz, H-4'), 7.34 (1H, d, J 2.3 Hz, H-6'). δC (100 MHz, CDCl3):
24.60 (CH2), 31.05 (CH2), 46.81 (CH), 109.34 (C), 117.48 (CH), 123.91 (C), 130.06 (CH), 130.87
(CH), 142.54 (C).  m/z (EI): 291 [M+•(81Br), 45%], 289 [M+•(79Br), 45], 216 [M+•(81Br) –
•CH2CH2CH2SH, 57], 214 [M+•(79Br) – •CH2CH2CH2SH, 57], 83 (100). HRMS: 290.9570 and
288.9598. C10H1281BrNS2 requires 290.9573, and C10H1279BrNS2 requires 288.9595.  Microanalysis:
C, 41.32; H: 4.11; N, 4.70%. C10H12BrNS2 requires C, 41.38; H, 4.17; N, 4.83%.
2-[2'-(N-Boc-amino)-5'-bromophenyl)]-1,3-dithiane 20.  A solution of 2-(2'-amino-5'-
bromophenyl)-1,3-dithiane 19 (7.73 g, 26.6 mmol, 1 eq.) and di-tert-butyldicarbonate (6.39 g, 29.3
mmol, 1.1 eq.) in THF (50 mL) was heated under reflux, under argon, for 15 h.  After this time, the
14
reaction mixture was poured into water and extracted into DCM (2×). The combined organics were
then washed with water (2×), dried (MgSO4) and concentrated. Recrystallisation from DCM-hexane
(1:6) gave carbamate 20 as a solid (7.26 g, 18.6 mmol, 70%); mp: 127-128 °C. Rf[SiO2, hexane-
DCM (2:1)]: 0.51. υmax(Golden Gate)/cm-1: 1687 cm-1 (C=O), 2929 (CH stretch), 2976 (CH stretch),
3241 (NH stretch), 3323 (NH stretch). δH (100 MHz, CDCl3): 1.54 (9H, s, tBu) 1.86-1.99 (1H, m,
Hax-5), 2.17-2.24 (1H, m, Heq-5), 2.94 (2H, dt, J 3.9 and 13.8 Hz, Heq-4 and Heq-6), 3.09 (2H, dt, J
2.3 and 13.5 Hz, Hax-4 and Hax-6), 5.23 (1H, s, H-2), 7.26 (1H, s, NH), 7.39 (1H, dd, J 2.3 and 8.8
Hz, H-4'), 7.54 (1H, d, J 2.3 Hz, H-6') 7.75  (1H, bd, J 8.1 Hz, H-3'). δC (400 MHz, CDCl3): 25.39
(CH2), 28.74 (CH3) 32.22 (CH2), 48.08 (CH), 81.31 (C), 116.98 (C), 124.65 (CH), 130 (C), 131.60
(CH), 132.38 (CH), 135.83 (C), 153.27 (C=O).  m/z (EI): 391 [M+•(81Br), 11 %], 389 [M+•(79Br),
10], 335 [M+•(81Br) – CH2=C(CH3)2, 71], 333 [M+•(79Br) - CH2=C(CH3)2, 65], 229 [M+•(81Br) –
CH2=C(CH3)2 and HSCH=CHCH2SH, 74], 227  [M+•(79Br) – CH2=C(CH3)2 and HSCH=CHCH2SH,
72], 57.1 (100). HRMS: 391.0096. C15H2081BrNO2S2 requires 391.0098.  Microanalysis: C, 46.34;
H, 5.26; N, 3.57; S: 16.53%. C15H20BrNO2S2 requires C, 46.15; H, 5.16; N, 3.59; S,16.43%.
2-[2'-(N-Boc-N-benzylamino)-5'-bromophenyl)]-1,3-dithiane 21.  NaH (0.38 g, 16 mmol, 1.2
eq.) was added portion-wise to a solution of 2-[2'-(N-Boc-amino)-5'-bromophenyl)]-1,3-dithiane 20
(5.14 g, 13.2 mmol, 1 eq.) and benzyl bromide (1.90 mL, 1.4 mmol, 1.2 eq.) in DMF (60 mL) at 0
°C under argon. The reaction mixture was then allowed to warm to rt and stirred for 3 h.  After this
time, the reaction mixture was carefully poured into iced water and extracted into EtOAc (2×). The
combined organics were washed with water (2× ), dried (MgSO4) and concentrated.
Recrystallisation from DCM-hexane gave N-benzylcarbamate 21 as a yellow solid (3.37 g, 7.02
mmol, 54%), mp: 155-157 °C. Rf[SiO2, hexane: DCM (2:1),]: 0.46. υmax(Golden Gate)/cm-1: 1687
cm-1 (C=O), 2904 (CH stretch), 2966 (CH stretch). δH (400 MHz, CDCl3): 1.40 (9H, s, tBu) 1.85-
1.98 (1H, m, Hax-5), 2.13-2.18 (1H, m, Heq-5), 2.80-3.02 (4H, m, H-4 and H-6), 4.30 (1H, d, J 14.4
Hz, PhCHAHB), 5.13 (1H, s, H-2), 5.25 (1H, d, J 14.1 Hz, PhCHAHB), 6.50 (1H, broad s, H-3'), 7.20
(1H, dd, J 1.6 and 8.3 Hz, H-4'), 7.22-7.35 (5H, m, Ar-H), 7.70 (1H, d, J 2.3 Hz, H-6'). δC (100
MHz, CDCl3): 25.39 (CH2), 28.47 (CH3) 32.49 (CH2), 32.80(CH2), 46.04 (CH), 53.75 (CH2) 81.31
(C), 122.15 (C), 127.93 (CH), 128.84 (CH) 129.32 (CH), 131.43 (CH), 132.04  (CH), 132.82 (CH),
138.18 (C), 138.63 (C), 139.29 (C), 155.35 (C=O). m/z (EI): 481 [M+•(81Br), 5 %], 479 [M+•(79Br),
4], 425 [M+•(81Br) – CH2=C(CH3)2, 24],  423 [M+•(79Br) – CH2=C(CH3)2, 22], 380 [M+•(81Br) –
•CO2C(CH3)3, 28], 378  [M+•(79Br) – •CO2C(CH3)3, 26], 334 [M+•(81Br) – CH2=C(CH3)2 and •CH2Ph,
60], 332 [M+•(79Br) – CH2=C(CH3)2 and •CH2Ph, 55], 91.1 (100). HRMS: 481.0566 and 479.0591.
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C22H2681BrNO2S2 requires 481.0569 and C22H2679BrNO2S2 requires 479.0588. Microanalysis: C,
54.75; H: 5.40; N: 3.03; S: 13.42%. C22H26BrNO2S2 requires C, 54.99; H, 5.45; N, 2.92; S, 13.35%.
2-[2'-(N-Boc-N-benzylamino)-5'-(4",4",5",5"-tetramethyl-1",3",2"-dioxaborolan-2"-yl)-
phenyl]- 1,3-dithiane 22.  Following the general procedure for Miyaura cross-coupling, a flask
charged with PdCl2(dppf) (0.19 g, 0.26 mmol, 3 mol%), KOAc (2.49 g, 25.40 mmol, 3 eq.) and
bis(pinacolato)diboron (2.37 g, 9.31 mmol, 1.1 eq.) was flushed with argon for 30 min. DMSO (45
mL) and aryl bromide 21 (4.07 g, 8.47 mmol, 1 eq.) were then added, the solution was degassed for
30 min and then stirred at 80 °C for 26 h.  The reaction mixture was cooled to rt and water was
added to the flask to induce precipitation. The grey solid was collected through filtration and
washed several times with water. The grey solid was then dissolved in EtOAc and a black solid was
removed by filtration through celite. Removal of solvent under reduced pressure gave a solid, which
was recrystallised from cyclohexane to give the aryl boronate 22 as a pale brown powder (3.99 g,
89%). M.p. 165-168 °C. Rf[SiO2, hexane-DCM (1:1)]: 0.33. υmax(Golden Gate)/cm-1: 1689 (C=O),
2928 (CH stretch), 2977 (CH stretch). δH (400 MHz, CDCl3): 1.32 (12H, s, CH3), 1.37 (9H, s, CH3),
1.87-2.20 (2H, m, H-5ax+eq), 2.80-3.05 (4H, m, H-4 and H-6), 4.32 (1H, d, J 14.5 Hz, PhCHAHB),
5.22 (1H, s, H-2), 5.23 (1H, d, J 14.8 Hz, PhCHAHB), 6.68 (1H, broad s, H-3'), 7.21-7.23 (5H, m,
Ar-H), 7.51 (1H, d, J 7.6 Hz, H-4'), 8.65 (1H, d, J 1.0 Hz, H-6'). δC (100 MHz, CDCl3, 353 K):
24.98 (CH3), 25.37 (CH2), 28.25 (CH3), 32.57 (CH2) 46.93 (CH), 54.00 (CH2), 80.58 (C), 83.99 (C),
127.33 (CH), 128.32 (CH), 128.85 (CH), 129.08 (CH), 134.94 (CH), 135.88 (CH), 136.28 (C),
138.48 (C), 142.35 (C), 155.23 (C=O).  m/z (EI):  527 (M+•, 10%), 471 [M+• – CH2=C(CH3)2, 25],
426 [M+• – •CO2C(CH3)3, 55], 380 [M+• – CH2=C(CH3)2 and •CH2Ph], 91 (+CH2Ph, 100). HRMS:
527.2335. C28H38NO4S2B requires 527.2335.  Microanalysis: C, 63.28; H, 7.22; N, 2.77%.
C28H38BNO4S2 requires C, 63.75; H, 7.26; N, 2.66%.
Resin-bound enol ether 25.  Cp2TiCl2 (0.94 g, 3.8 mmol, 12 eq.), magnesium turnings (0.10 g, 4.1
mmol, 13 eq., predried at 250 °C overnight) and freshly activated 4 Å molecular sieves (0.25 g)
were heated, gently, under reduced pressure (0.3 mmHg) for about 1 min and then placed under
argon. Dry THF (5 mL) was added followed by dry P(OEt)3 (1.3 mL, 7.6 mmol, 24 eq.). After
stirring for 3 h at rt, a solution of the dithiane 22 (0.49 g, 0.95 mmol, 3 eq.) in dry THF (4 mL) was
added to the mixture and stirring continued for 15 min.  The solution was added to a flask
containing resin-bound ester 24 contained in a MacroKanTM [0.315 meq. prepared from 160 mg of
Merrifield resin with a loading of 1.97 meq. (chloride) g-1] and pre-swollen in THF (6 mL) under
argon.  After 17 h the reactor was removed from the flask and washed with THF (5×) then
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alternately with MeOH and DCM (5×), and finally with MeOH then Et2O. The reactor containing
the resin-bound enol ether 25 was then dried under vacuum.
N-Benzyl-2-phenethyl-5-(4',4',5',5'-tetramethyl-1',3'-dioxaborolan-2'-yl)indole 26.  A
MacroKanTM containing the resin-bound enol ether 25 (0.315 meq.) was shaken with trifluoroacetic
acid (1%) in DCM (5 mL) for 1.5 h.  The solution was removed and the MacroKanTM was washed
with DCM (3×). Combined organics were concentrated under reduced pressure. The residue was
placed under argon, dissolved in dry DCM (5 mL), and stirred at 0 °C under argon.  Trifluoroacetic
acid (0.5 mL, 6.5 mmol) was added drop-wise and the mixture was allowed to warm to rt and then
stirred for 2 h. After this time, the reaction mixture was poured into saturated aqueous sodium
bicarbonate and extracted into DCM (2×). The combined organics were washed with saturated
aqueous sodium bicarbonate (2×), dried over magnesium sulfate, and concentrated under reduced
pressure to give indole 26 as a brown oil (46 mg, 34%). Rf[SiO2, hexane: DCM (1:1)]: 0.25.
υmax(Golden Gate)/cm-1: 2926 cm-1 (CH stretch), 1351 (B-O). δH (400 MHz, CDCl3): 1.35 (12H, s,
4 × CH3), 2.96 (4H, s, CH2CH2Ph), 5.25 (2H, s, CH2, NCH2Ph), 6.40 (1H, s, H-3), 6.89 (2H, dd, J
1.8 and 8.0 Hz, ArH), 7.10-7.26 (9H, m, Ar-H), 7.58 (1H, dd, J 1.0 and 8.2 Hz, H-6), 8.12 (1H, s,
H-4). δC (100 MHz, CDCl3): 24.88 (CH3), 28.63 (CH2), 34.82 (CH2), 46.28 (CH2), 83.33 (C),
100.36 (CH), 108.73 (CH), 125.83 (CH), 126.13 (CH), 127.25 (CH), 127.78 (CH), 128.33 (CH),
128.40 (CH), 128.73 (CH), 137.65 (C), 139.20 (C), 140.56 (C). 141.13 (C).  m/z (EI):  437 (M+•,
42%), 346 (M+• – •CH2Ph, 100).  HRMS: 437.2524 (M+•). C29H3211BNO2 requires 437.2526.
N-Benzyl-5-(4'-methylphenyl)-2-phenethylindole 28. Pd(PPh3)4 (15 mg, 4 mol%) was added to a
stirring suspension of the resin-bound enol ether 25 (0.315 meq.) contained in a MacroKanTM,
Cs2CO3 (0.54 g, 1.7 mmol, 5.3 eq.) and 4-iodotoluene (350 mg, 1.6 mmol, 5.1 eq.), in degassed
DMF (15 mL) with H2O (5.6 µL, 1 eq.) under argon. The suspension was stirred at 80 °C for 17 h.
The mixture was allowed to cool and the MacroKanTM was separated from the reaction mixture and
washed with 9:1 DMF-H2O (3×), alternately with MeOH and DCM (3×), and finally with MeOH
and Et2O. The MacroKanTM containing resin-bound enol ether 27 was then dried under vacuum
before being cleaved, in the same way as for the synthesis of boronate 26, to give indole 28 as a
brown oil (55 mg, 45%). Rf[SiO2, hexane-DCM (1:1)]: 0.71. υmax(Golden Gate)/cm-1: 1452 (Ar),
1473 (Ar), 2919 (CH stretch). δH (400 MHz, CDCl3):  2.37 (3H, s, CH3), 2.93-3.02 (4H, m,
CH2CH2Ph), 5.24 (2H, s, N-CH2Ph), 6.42 (1H, s, H-3), 6.94 (2H, d, J 8.2 Hz, H-2' and H-6'), 7.13
(2H, d, J 8.3 Hz, ArH), 7.17-7.28 (9H, m, Ar-H), 7.34 (1H, dd, J 1.7 and 8.5 Hz, H-6), 7.53 (2H, d,
J 8.1 Hz, H-3' and H-5'), 7.78 (1H, d, J 1.5 Hz, H-4).  δC (100 MHz, CDCl3): 21.04 (CH3), 28.68
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(CH2), 34.91 (CH2), 46.42 (CH2), 100.03 (CH), 109.46 (CH), 118.27 (CH), 120.72 (CH), 125.90
(CH), 126.16 (CH), 127.14 (CH), 127.29 (CH), 128.33 (CH), 128.44 (CH), 128.52 (C), 128.77
(CH), 129.31 (CH), 133.03 (C), 135.74 (C), 136.61 (C), 137.77 (C), 139.75 (C), 141.10 (C). 141.15
(C).  m/z (EI): 401 (M+•, 83), 310 (M+• – •CH2Ph, 100). HRMS: 401.2148. C30H27N requires
401.2144.
N-Benzyl-5-(4'-methoxyphenyl)-2-phenethylindole 29. In the same way, resin-bound enol ether
25 (0.315 meq.) and 4-iodoanisole (370 mg, 1.6 mmol) yielded indole 29 as a brown oil (34 mg,
26%). Rf[SiO2, hexane: DCM (1:1)]: 0.50. υmax(Golden Gate)/cm-1: 1453 cm-1 (Ar), 1474 (Ar), 2936
(CH stretch). δH (400 MHz, CDCl3): 2.85-2.95 (4H, m, CH2CH2Ph), 3.74 (3H, s, OCH3), 5.17 (2H,
s, N-CH2Ph), 6.34 (1H, s, H-3), 6.85-6.89 (4H, m, Ar-H), 7.04-7.20 (9H, m, Ar-H), 7.23 (1H, dd, J
1.7 and 8.5 Hz, H-6), 7.48 (2H, m, Ar-H), 7.66 (1H, d, J 1.5 Hz, H-4). δC (100 MHz, CDCl3): 28.68
(CH2), 34.88 (CH2), 46.40 (CH2), 55.29 (CH3), 99.94 (CH), 109.46 (CH), 114.02 (CH), 118.00
(CH), 120.57 (CH), 125.88 (CH), 126.16 (CH), 127.28 (CH), 128.22 (CH), 128.33 (CH), 128.43
(CH), 128.52 (C), 128.77 (CH), 132.75 (C), 135.26 (C), 136.41 (C), 137.76 (C), 141.09 (C), 141.14
(C). 158.34 (C).  m/z (EI): 417 (M+•, 61), 326 (M+• – •CH2Ph, 100), 91 (+CH2Ph, 31). HRMS:
417.2093. C30H27NO required 417.2095.
N-Benzyl-5-(4'-nitrophenyl)-2-phenethylindole 30. In the same way, resin-bound enol ether 25
(0.315 meq.) and 4-iodonitrobenzene (0.45 g, 1.6 mmol), yielded indole 30 as a brown oil (45 mg,
34%). Rf[SiO2, hexane: DCM (1:1)]: 0.47. υmax(Golden Gate)/cm-1:  1338 cm-1 (NO2), 1453 (Ar),
1512 (NO2), 3024 (CH stretch). δH (400 MHz, CDCl3): 2.98-3.05 (4H, m, CH2CH2Ph), 5.29 (2H, s,
N-CH2Ph), 6.40 (1H, s, H-3), 6.95 (2H, d, J 6.6 Hz, Ar-H), 7.15 (2H, d, J 6.9 Hz. Ar-H), 7.16-7.31
(7H, m, Ar-H), 7.37 (1H, dd, J 1.7 and 8.5 Hz, H-6), 7.74 (2H, d, J 8.8 Hz, Ar-H), 7.84 (1H, d, J
1.6 Hz, H-4), 8.24 (2H, d, J 8.8 Hz, H-3' and H-5'). δC (100 MHz, CDCl3): 28.60 (CH2), 34.73
(CH2), 46.47 (CH2), 100.39 (CH), 109.96 (CH), 119.12 (CH), 120.59 (CH), 123.97 (CH), 125.80
(CH), 126.24 (CH), 127.43 (CH), 128.29 (CH), 128.46 (CH), 128.65 (C), 128.83 (CH), 130.31 (C),
137.34 (C), 137.47 (C), 140.88 (C), 141.98 (C), 146.13 (C). 149.11 (C). m/z (EI): 432 (M+•, 44%),
341 (M+• – •CH2Ph, 100), 295 (M+• – •CH2Ph  and NO2, 13), 91 (+CH2Ph, 51). HRMS: 433.1917.
C29H24N2O2 requires 433.1916.
2-[2'-amino-5'-(4", 5"-tetramethyl-1", 3", 2"-dioxaborolan-2"-yl]-1,3-dithiane 34.  tert-
Butyllithium (69.5 mL, 1.7 M, 118 mmol) was added drop-wise over a period of 1 h 45 min to a
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cooled (–80 °C to –89 °C) to a stirred solution of aryl azide 18 (12.1 g, 38.1 mmol) in dry THF (120
mL) under argon ensuring the temperature did not exceed –80 °C. The reaction mixture was stirred
for 15 min at –80 °C and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (25.6 mL, 126
mmol) was added drop-wise over 45 min and the resulting mixture was stirred for 1 h 30 min before
being allowed to warm to rt and stirred overnight.  Water buffered to pH 7 was added, and the
mixture extracted with DCM (3×).  The combined organics were washed with water and then brine
(3×) and dried (MgSO4). Removal of solvent under reduced pressure gave a dark brown oil.
Crystallisation from pentane and ethyl acetate gave the boronate 34 as a brown solid (4.97 g, 39%).
Mp 190 – 193 °C. Rf [SiO2, DCM/Hexane]: 0.70. υmax(Golden Gate)/cm-1: 1607 (Ar), 3402 (NH2).
δH (400 MHz, CDCl3): 1.23 (12H, s, CH3), 1.82-1.99 (1H, m, Hax-5), 2.09-2.21 (1H, m, Heq-5), 2.83
(2H, td, J 4.0  and 13.0 Hz, Heq-4 and Heq-6), 3.01 (2H, dt, J 2.0  and 13.0 Hz, Hax-4 and Hax-6), 4.40
(2H, broad s, NH2), 5.26 (1H, s, H-2), 6.57 (1H, d, J 8.1 Hz, H-3'), 7.48 (1H, dd, J 1.4  and 8.1 Hz,
H-4'), 7.63 (1H, d, J 1.3 Hz, H-6'). δC (100 MHz, CDCl3): 24.89 (CH3), 25.29 (CH2), 32.00 (CH2),
49.97 (CH), 83.40 (C), 116.16 (CH), 121.50 (C), 136.21 (CH), 136.29 (CH), 147.82 (C). m/z (EI):
337 (M+•, 79%), 262 (100), HRMS: 337.1338. C16H24O2NS2B requires 337.1341. Microanalysis: C,
57.02; H: 7.17; N: 4.22%. C16H24O2NS2B requires C, 56.97; H, 7.17; N, 4.15%.
2-[2'-tert-Butoxycarboxyamino-5'-(4", 5"-tetramethyl-1", 3", 2"-dioxaborolan-2"-yl]-1,3-
dithiane 35.  A solution of amine 34 (5.81 g, 17.2 mmol) in dry THF (150 mL) and (Boc)2O (7.89
g, 36.2 mmol) was heated under reflux for 12 h under argon. After this time an additional
equivalent of (Boc)2O (3.75 g) was added and the reaction mixture stirred at reflux for a further 24
h. The reaction mixture was then allowed to cool to rt and quenched with water. The mixture was
extracted with DCM (2×) and the combined organics washed with water (2×) and dried (MgSO4).
Removal of solvent under reduced pressure gave a yellow solid. Column chromatography eluting
with hexane-EtOAc (4:1) gave carbamate 35 as a pale yellow solid (5.41 g, 71%). Mp 99 – 101 °C.
Rf [SiO2, hexane-EtOAc (4:1)]: 0.45. υmax(Golden Gate)/cm-1: 1366 (B-O), 1478 (Ar), 1682 (C=O).
δH (400 MHz, CDCl3): 1.32 (12H, s, CH3), 1.54 (9H, s, tBu), 1.91 (1H, ttd, 3.0 , 12.5  and 14.1 Hz,
Hax-5), 2.17 (1H, ttd, J 2.3, 3.9 and 14.2 Hz, Heq-5), 2.93 (2H, ddd, J 3.3, 3.9  and 14.4, Heq-4 and
Heq-6), 3.06 (2H, ddd, J 2.3, 12.5 and 14.4 Hz, Hax-4 and Hax-6), 5.34 (1H, s, H-2), 7.69 (1H, broad
s, NH), 7.71 (1H, dd, J 1.4  and 8.3 Hz, H-4'), 7.78 (1H, d, J 1.4 Hz, H-6'), 7.96 (1H, d, J 8.3 Hz, H-
3'). δC (100 MHz, CDCl3): 24.86 (CH3), 25.17 (CH2), 28.40 (CH3), 31.93 (CH2), 49.52 (CH), 80.59
(C), 83.73 (C), 85.17 (CH), 135.61 (CH), 135.91 (CH), 139.62 (C), 146.75 (C), 152.75 (C). m/z
(EI): 437 (M+•, 6%), 380 (71), 274 (M+•, –•C(CH3)3 and HSCH=CHCH2SH, 100). HRMS: 437.1866.
C21H32O4NS2B requires 437.1867.
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2-[2'-Aminosilylcarbamate-5'-(4", 5"-tetramethyl-1", 3", 2"-dioxaborolan-2"-yl]-1,3-dithiane
36.  A solution of lithium diisopropylamide (1.80 mL, 2.0 M, 3.4 mmol) was added drop-wise to a
cooled stirred solution of carbamate 35 (1.22 g, 2.8 mmol) and TMSCl (0.42 mL, 3.4 mmol) in
THF (30 mL) at –78 °C under an inert atmosphere of argon. The reaction mixture was then allowed
to warm to rt over 45 min and was allowed to stir for a further 1 h at RT. After this time, the solvent
was removed in vacuo and ether (30 mL) was added. The resulting white solid was filtered off and
the ethereal solution concentrated to furnish target N-silylcarbamate 36 as an off-white solid (1.40
g, 98%). δH (400 MHz, CDCl3): 0.24 (9H, s, Si-CH3), 1.33 (12H, s, CH3), 1.54 (9H, s, tBu), 1.92-
2.05 (1H, m, Hax-5), 2.14-2.22 (1H, m, Heq-5), 2.88-3.07 (4H, m, Heq-4, Heq-6, Hax-4 and Hax-6), 5.21
(1H, s, H-2), 6.94 (1H, d, J 7.7 Hz, H-3'), 7.65 (1H, dd, J 1.3 and 7.7 Hz, H-4'), 8.06 (1H, d, J 1.3
Hz, H-6'). δC (100 MHz, CDCl3): 0.60 (CH3), 23.52 (CH3), 23.82 (CH2), 27.05 (CH3), 30.59 (CH2),
48.18 (CH), 79.26 (C), 82.39 (C), 119.35 (C), 126.95 (C), 134.27 (CH), 134.58 (CH), 138.28 (C),
151.41 (C). m/z (EI): 509 (M+•, 3%), 452 [(M+• – •C(CH3)3 55)], 408 [(M+• – •C(CH3)3 and CO2 60)],
346 (M+•, – •C(CH3)3 and HSCH=CHCH2SH, 100). HRMS: 509.2263. C24H40O4NS2BSi requires
509.2261.
Resin-bound enol ether 38.  Resin-bound enol ether was prepared in the same way as resin bound
enol ether 25, but using dithiane 36 instead of dithiane 22 with resin-bound ester 24 contained in a
MacroKanTM [0.325 meq. prepared from 170 mg of Merrifield resin with a loading of 1.91 meq.
(chloride) g-1].  
N-Boc-2-phenylethyl-5-(4", 5"-tetramethyl-1", 3", 2"-dioxaborolan-2"-yl]-indole 39.  A
MacroKanTM containing the resin-bound enol ether 25 (0.325 meq.) was shaken with trifluoroacetic
acid (1%) in DCM (5 mL) for 1.5 h.  The solution was removed and the reactor was washed with
DCM (3×). Combined organics were concentrated under reduced pressure gave indole 39 as a
purple solid (81 mg, 56%). Mp 101-104 ˚C.  Rf [SiO2, DCM]: 0.76. υmax(Golden Gate)/cm-1: 1734
(C=O), 2976 (CH). δH (400 MHz, CDCl3): 1.36 (12H, s, CH3), 1.68 (9H, s, tBu), 3.01 (2H, t, J 8.4
Hz, H-2'), 3.32 (2H, t, J 8.4 Hz, H-1'), 6.33 (1H, s, H-3), 7.18-7.29 (5H, m, Ar-H), 7.69 (1H, dd, J
0.9 and 8.4 Hz, H-6), 7.92 (1H, d, J 0.9 Hz, H-4), 8.04 (1H, d, J 8.4 Hz, H-7). δC (100 MHz,
CDCl3): 24.93 (CH3), 28.27 (CH3), 31.76 (CH2), 35.20 (CH2), 83.65 (C), 83.95 (C), 107.64 (CH),
114.94 (CH), 126.00 (CH), 127.06 (CH), 128.38 (CH), 128.43 (CH) 128.90 (C), 129.74 (CH),
138.69 (C), 141.47 (C), 141.59 (C), 150.52 (C). m/z (EI): 447 (M+•, 19%), 391 (M+• – CH2=C(CH3)2,
44), 300 (82), 83 (100). HRMS: 447.2577. C27H34O4NB requires 447.2571.
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N-Boc-5-(4'-methylphenyl)-2-(2"-phenylethyl)indole 40.  Pd(PPh3)4 (14.4 mg, 4 mol%) was
added to a stirring suspension of resin-bound enol ether 25 (0.325 meq.) contained in a
MacroKanTM, Cs2CO3 (511 mg, 1.5 mmol, 4.6 eq.) and 4-iodotoluene (338 mg, 1.55 mmol, 4.8 eq.),
in degassed DMF (15 mL) with H2O (5.6 µL, 0.31 mmol, 0.96 eq.) under argon. The mixture was
stirred at 80 °C for 5 h.  Cleavage in the same way as for indole 39 gave  indole 40  as a brown solid
(74.1 mg, 53%). Mp 75-78 ˚C.  Rf [SiO2, DCM]: 0.76. υmax(Golden Gate)/cm-1: 1468 (Ar), 1731
(C=O), 2929 (CH), 2077 (CH), 3025 (Ar-H). δH (400 MHz, CDCl3): 1.63 (9H, s, tBu), 2.33 (3H, s,
CH3), 2.97 (2H, t, J 8.4 Hz, CH2Ph), 3.28 (2H, t, J 8.4 Hz, CH2CH2Ph), 6.32 (1H, s, H-3), 7.14-7.27
(5H, m, Ar-H), 7.22 (2H, d, 8.8 Hz, Ar-H), 7.40 (1H, dd, J 2.0 and 8.8 Hz, H-6), 7.47 (2H, d, J 8.8
Hz, Ar-H), 7.56 (1H, d, J 2.0 Hz, H-4), 8.03 (1H, d, J 8.8 Hz, H-7). δC (100 MHz, CDCl3): 21.12
(CH3), 28.32 (CH3), 32.52 (CH2), 35.25 (CH2), 83.93 (C), 107.57 (CH), 115.80 (CH), 118.06 (CH),
122.71 (CH), 126.07 (CH), 127.14 (CH), 128.45 (CH), 128.47 (CH), 129.78 (CH), 129.87 (C),
135.85 (C), 135.91 (C), 136.49 (C), 138.84 (C), 141.52 (C), 142.31 (C), 150.62 (C). m/z (EI): 411
(M+•, 34%), 355 (M+• – CH2=C(CH3)2, 56), 264 (95), 290 (100). HRMS: 411.2199. C28H29O2N
requires 411.2198.
N-Boc-5-(4'-methoxyphenyl)-2-(2"-phenylethyl)indole 41.  In the same way, but using 4-
iodoanisole (365 mg) as the aryl iodide in the Suzuki cross coupling gave indole 41 as a dark brown
solid (74.3 mg, 54%). Mp 80-83 ˚C.  υmax(Golden gate)/cm-1: 1468 (Ar), 1731 (C=O), 2929 (CH).
δH (400 MHz, CDCl3): δ 1.61 (9H, s, tBu), 2.95 (2H, t, J 7.8 Hz, CH2Ph), 3.26 (2H, t, J 7.8 Hz,
CH2CH2Ph), 3.76 (3H, s, OCH3), 6.29 (1H, s, H-3), 6.89 (2H, d, J 2.0 Hz, H-3' and H-5'), 7.09-7.25
(5H, m, Ph) 7.34 (1H, dd, 2.0 and 8.8 Hz, H-6), 7.48 (2H, d, J 2.0 Hz,  H-2' and H-6'), 7.52 (1H, d,
J 2.0 Hz, H-4), 8.03 (1H, d, J 8.8 Hz, H-7). δC (100 MHz, CDCl3): 28.31 (CH3), 31.83 (CH2), 35.24
(CH2), 55.40 (CH3), 82.87 (C), 107.43 (CH), 114.20 (CH), 115.79 (CH), 117.79 (CH), 122.66 (CH),
126.05 (CH), 128.26 (CH), 128.43 (CH), 128.64 (CH), 128.79 (C), 133.27 (C), 134.51 (C), 134.58
(C), 140.43 (C), 141.22 (C), 149.51 (C), 157.70 (C).  Mass (m/z): LRMS (EI+): 427 (M+•, 52%), 371
(M+• – CH2=C(CH3)2, 87), 280 (100). HRMS: 427.2148. C28H29O3N requires 427.2147.
N-Boc-2-(2'-phenylethyl)-5-(2"-thiophenyl)indole 42.  In the same way, but using 2-
iodothiophene (322 mg) as the aryl iodide in the Suzuki cross coupling gave indole 42 as a dark
brown solid (81 mg, 62%). Mp 108-110 ˚C. υmax(Golden gate)/cm-1: 1470 (Ar), 1726 (C=O), 2854
(CH), 2925 (CH).  δH (400 MHz, CDCl3): 1.68 (9H, s, tBu), 3.03 (2H, t, J 8.0 Hz, CH2Ph), 3.33
(2H, t, J 8.0 Hz, CH2CH2Ph), 6.35 (1H, s, H-3), 7.02-7.08 (1H, m, H-4"), 7.18-7.31 (7H, m, H-5",
H-3" and Ph) 7.51 (1H, dd, 2.0 and 8.8 Hz, H-6), 7.66 (1H, d, J 2.0 Hz, H-4), 8.07 (1H, d, J 8.8 Hz,
H-7).  δC (100 MHz, CDCl3): 28.25 (CH3), 31.76 (CH2), 35.12 (CH2), 84.05 (C), 107.45 (CH),
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115.90 (CH), 117.08 (CH), 121.76 (CH), 122.61 (CH), 124.08 (CH), 126.03 (CH), 127.94 (CH),
128.40 (CH), 128.42 (CH), 129.30 (C), 129.80 (C), 135.99 (C), 141.39 (C), 142.56 (C), 145.16 (C),
150.41 (C).  m/z (EI): 403 (M+•, 43%), 347 (M+• – CH2=C(CH3)2, 67], 212 (100). HRMS: 403.1607.
C25H25O3NS requires 403.1606.
N-Boc-2-(2'-phenylethyl)-5-(3"-pyridyl)indole 43. In the same way, but using 3-iodopyridine
(312 mg) as the aryl iodide in the Suzuki cross coupling gave indole 43 as its TFA salt (105 mg) as
a dark brown solid. A portion of the salt (40.0 mg) was treated with NaHCO3 and extracted into
DCM. The combined organics were concentrated under reduced pressure to give the indole 43 (27.6
mg, 58%) as a brown oil.  υmax (KBr)/cm-1: 1496 (Ar), 1733 (C=O), 2854 (CH), 2974 (CH). δH (400
MHz, CDCl3): 1.64 (9H, s, tBu), 2.98 (2H, t, J 7.8 Hz, CH2Ph), 3.30 (2H, t, J 7.8 Hz, CH2CH2Ph),
6.35 (1H, s, H-3), 7.12-7.23 (5H, m, Ph) 7.40 (1H, dd, 2.0 and 8.8 Hz, H-6), 7.58 (1H, d, J 2.0 Hz,
H-4), 7.84-7.87 (1H, m, H-5"), 8.12 (1H, d, J 8.8 Hz, H-7), 8.52 (1H, d, J 8.6 Hz, H-4"), 8.68 (1H,
d, J 2.2 and 8.6 Hz, H-6"), 9.04 (1H, d, J 2.2 Hz, H-2").  δC (100 MHz, CDCl3): 27.25 (CH3), 30.74
(CH2), 34.12 (CH2), 83.15 (C), 106.41 (CH), 115.13 (CH), 117.30 (CH), 121.51 (CH), 125.03 (CH),
126.74 (CH), 127.39 (C), 128.14 (CH), 128.31 (CH), 130.21 (C), 137.14 (C), 139.21 (CH), 140.31
(CH), 141.72 (C), 140.07 (C), 142.73 (CH), 143.42 (C), 149.93 (C).  m/z (EI): 398 (M+•, 21%), 342
[M+• – CH2=C(CH3)2, 48], 251 (65), 207 (100), HRMS: 398.1996.  C26H26O2N2 requires 398.1994.
N -Boc-5-(4"-nitrophenyl)-2-(2'-phenylethyl)indole 44 and 1-[2'-(N -Boc- 4”-
nitrophenylamino)-5'-(4"'-nitrophenyl)phenyl]-4-phenylbutan-2-one 45. In the same way, but
using 1-iodo-4-nitrobenzene (391 mg) and heating at 80 °C for only 2 h in the Suzuki cross-
coupling, gave a 5:1 mixture of indole 44 and ketone 45 (97 mg, 68%) after cleavage.  Pure samples
of each compound were obtained by chromatography (DCM).  Indole 44 was isolated as a yellow
solid.  Rf [SiO2, DCM]: 0.85. υmax(Golden Gate)/cm-1: 1341 (NO2), 1516 (NO2), 1595 (Ar), 1734
(C=O), 2926 (CH), 2968 (CH). δH (400 MHz, CDCl3): 1.63 (9H, s, CH3), 2.97 (2H, t, J 7.9 Hz,
CH2Ph), 3.28 (2H, t, J 7.9 Hz, CH2CH2Ph), 6.33 (1H, s, H-3), 7.13-7.22 (5H, m, Ar-H), 7.41 (1H,
dd, J 1.9 and 8.7 Hz, H-6), 7.61 (1H, d, J 1.7 Hz, H-4), 7.67 (2H, d, J 8.8 Hz, H-2" and 6"), 8.09
(1H, d, J 8.7 Hz, H-7), 8.19 (2H, d, J 8.8 Hz, H-3" and 5").  δC (100 MHz, CDCl3): δ 28.30 (CH3),
31.77 (CH2), 35.16 (CH2), 84.39 (C), 107.50 (CH), 116.57 (CH), 119.43 (CH), 122.73 (CH), 124.10
(CH), 126.14 (CH), 128.38 (CH), 127.71 (CH), 128.42 (CH), 130.03 (C), 133.26 (C), 136.93 (C),
141.29 (C), 143.04 (C), 146.67 (C), 148.24 (C), 150.34 (C). m/z (EI): 442 (M+•, 16%), 386 (M+• –
CH2=C(CH3)2, 63), 295 (86), 57 (100), HRMS: 442.1893. C27H26O4N2 requires 442.1893. Ketone 45
was isolated as an orange solid. Rf [SiO2, DCM]: 0.48.  υmax(Golden Gate)/cm-1: 1342 (NO2), 1517
(NO2), 1592 (Ar), 1717 (C=O), 2924 (CH). δH (400 MHz, CDCl3): δ 1.38 (9H, s, CH3), 2.71 (4H, m,
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CH2CH2Ph), 3.46 (1H, d, J 15.7 Hz), 3.54 (1H, d, J 15.7 Hz), 7.03-7.21 (5H, m, Ar-H), 7.25 (1H, d,
J 8.2 Hz, H-3'), 7.29 (2H, d, 9.3 Hz, H-2" and H-6"), 7.41 (1H, d, J 2.2 Hz, H-6'), 7.55 (1H, dd, J
2.2 and 8.2 Hz, H-4'), 7.67 (2H, d, J 8.8 Hz, H-2"' and H-6"'), 8.04 (2H, d, J 9.3 Hz, H-3" and H-
5"), 8.25 (2H, d, J 8.8 Hz, H-3"' and H-5"').  δC (100 MHz, CDCl3): 28.09 (CH3), 29.60 (CH2),
45.18 (CH2), 83.28 (C), 123.48 (CH), 124.21 (CH), 124.31 (CH), 126.31 (CH), 127.54 (CH),
127.99 (CH), 128.28 (CH), 128.56 (CH), 130.59 (CH), 131.27 (CH), 133.50 (C), 138.96 (C),
140.48 (C), 140.59 (C), 143.70 (C), 146.03 (C), 147.45 (C), 147.64 (C), 152.65 (C), 205.36 (C).
m/z (FAB+): 582 (M + H+, 22%), 526 [(M + H)+– CH2=C(CH3)2, 40], 482 (58), 481 (32), 59 (100),
HRMS: 582.2240. C33H32O7N3 requires M + H+, 582.2240.
Library Synthesis
Resin-bound enol ether 47.  Cp2TiCl2 (3.623 g, 14.5 mmol, 12 eq.), magnesium turnings (0.391 g,
15.9 mmol, 13 eq., predried at 250 °C overnight) and freshly activated 4 Å molecular sieves (703
mg) were heated, gently, under reduced pressure (0.3 mmHg) for about 1 min and then placed under
argon. Dry THF (20 mL) was added followed by dry P(OEt)3 (5.2 mL, 29 mmol, 24 eq.). After
stirring for 3 h at rt, a solution of the dithiane 36 (1.85 g, 3.6 mmol, 3 eq.) in dry THF (20 mL) was
added to the mixture and stirring continued for 15 min.  After this time,13 MiniKansTM, each
containing one of the resin-bound esters 46A-H [93 µeq./MiniKanTM prepared from 46.5 mg of
Merrifield resin with a loading of 2.0 meq. (chloride) g-1], that had been purged with argon were
added.  After 17 h the MiniKansTM were removed from the flask and washed with THF (5×) then
alternately with MeOH and DCM (5×), and finally with MeOH then Et2O. The 13 MiniKansTM
containing one of the resin-bound enol ethers 47A-H were then dried under vacuum.  The same
procedure was employed for all 8 resin-bound esters 46A-H,  using 104 MiniKansTM in total.
N-Boc-2-(2'-phenylethyl)-5-(4", 5"-tetramethyl-1", 3", 2"-dioxaborolan-2"-yl)-indole 48A.
One MiniKanTM containing resin-bound enol ether 47A (93 µeq.) was shaken with trifluoroacetic
acid (1%) in DCM (5 mL) for 1.5 h.  The solution was removed and the reactor was washed with
DCM (3×). Combined organics were concentrated under reduced pressure gave indole 47A (23.7
mg, 57%). 1H NMR data as reported for indole 39 above.
N-Boc-2-propyl-5-(4', 5'-tetramethyl-1', 3', 2'-dioxaborolan-2'-yl)indole 48B.  In the same way,
one MiniKanTM containing resin-bound enol ether 47B (93 µeq.) gave indole 48B (21.8 mg,
61%).  δH (400 MHz, CDCl3): 1.03 (2H, t, J 7.2 Hz, CH3CH2), 1.37 (12H, s, CH3), 1.67 (9H, s, tBu),
23
2.93–2.98 (4H, m, CH2CH2), 6.34 (1H, s, H-3), 7.65 (1H, dd, J 1.2 and 8.4 Hz, H-6), 8.06 (1H, d, J
1.2 Hz, H-4), 8.21 (1H, d, J 8.4 Hz, H-7).
N-Boc-2-(3'-phenylpropyl)-5-(4", 5"-tetramethyl-1", 3", 2"-dioxaborolan-2"-yl)indole 48C. In
the same way, one MiniKanTM containing resin-bound enol ether 47C (93 µeq.) gave indole 48C
(25.7 mg, 60%). δH (400 MHz, CDCl3): 1.33 (12H, s, CH3), 1.66 (9H, s, tBu), 2.04 (2H, qn, J 7.4
Hz, CH2CH2CH2), 2.73 (2H, t, J 7.4 Hz, CH2CH2CH2Ph), 3.03 (2H, t, J 7.4 Hz, CH2Ph), 7.19–7.29
(5H, m, ArH), 6.34 (1H, s, H-3), 7.67 (1H, dd, 1.6 and 8.4 Hz, H-6), 7.93 (1H, d, J 1.6 Hz, H-4),
8.08 (1H, d, J 8.4 Hz, H-7).
N-Boc-2-[2'-(3"-pyridyl)]-5-(4"', 5"'-tetramethyl-1"', 3"', 2"'-dioxaborolan-2"'-yl)indole 48D.
In the same way, one MiniKanTM containing resin-bound enol ether 47D (93 µeq.) gave indole 48D
(24.2 mg, 58%). δH NMR  (400 MHz, DMSO-d6): 1.21 (9H, s, tBu), 1.24 (12H, s, CH3),  2.76 (2H,
t, J 7.2 Hz, CH2CH2), 3.17 (2H, t, J 7.2 Hz, CH2CH2), 6.32 (1H, s, H-3), 7.12 (1H, dd, 1.6 and 8.4
Hz, H-6), 7.22 (1H, d, J 1.6 Hz, H-4), 7.25 (1H, broad dd, J 4.8 Hz and 7.7 Hz, H-5"), 7.62 (1H, d,
J 8.4 Hz, H-7), 7.67 (1H, broad d, J 7.8 Hz, H-4"), 8.41 (1H, broad s, H-2"), 8.43 (1H, broad d, 4.7
Hz, H-6").
N-Boc-2-(3'-phenoxypropyl)-5-(4", 5"-tetramethyl-1", 3", 2"-dioxaborolan-2"-yl)indole 48E.
In the same way, one MiniKanTM containing resin-bound enol ether 47E (93 µeq.) gave indole 48E
(17.5 mg, 42%).  δH (400 MHz, CDCl3): 1.36 (12H, s, CH3), 1.68 (9H, s, tBu), 2.19 (2H, qn, J 7.4
Hz, CH2CH2CH2),  3.20 (2H, t, J 7.2 Hz, CH2CH2CH2OPh), 4.04 (2H, t, J 7.4 Hz, CH2OPh), 6.37
(1H, s, H-3), 6.88–6.95 (3H, m, ArH), 7.27–7.29 (2H, m, ArH), 7.67 (1H, dd, 1.2 and 8.4 Hz, H-6),
7.92 (1H, d, J 1.2 Hz, H-4), 8.07 (1H, d, J 8.4 Hz, H-7).
N -Boc-2-[2'-(3",4"-dimethoxyphenyl)ethyl]-5-(4"', 5"'-tetramethyl-1"', 3"', 2"'-
dioxaborolan-2"'-yl)indole 48F.  In the same way, one MiniKanTM containing resin-bound enol
ether 47F (93 µeq.) gave indole 48F (27.1 mg, 58%).    δH (400 MHz, CDCl3): 1.36 (12H, s, CH3),
1.67 (9H, s, tBu), 2.96 (2H, t, J 7.2 Hz, H-2'), 3.30 (2H, t, J 7.4 Hz, H-1'), 3.81 (3H, s, OCH3), 3.86
(3H, s, OCH3), 6.32 (1H, s, H-3), 6.71 (1H, d, J 1.6 Hz, H-2"), 6.77–6.78 (2H, m, H-5" and H-6"),
7.68 (1H, dd, 1.2 and 8.4 Hz, H-6), 7.92 (1H, d, J 1.2 Hz, H-4), 8.06 (1H, d, J 8.4 Hz, H-7).
N-Boc-2-[2'-(piperidin-4"-yl)ethyl]-5-(4"', 5"-tetramethyl-1"', 3"', 2"'-dioxaborolan-2"'-
yl)indole, trifluoroacetate salt 48G'. In the same way, one MiniKanTM containing resin-bound enol
ether 47E (93 µeq.) gave indole 48G' (36.6 mg, 73%).  δH (400 MHz, CDCl3): 1.37 (12H, s, CH3),
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1.53–1.56 (5H, m, H-pip), 1.69 (9H, s, tBu), 2.00-2.10 (2H, m, piperidine),  2.90-3.10 (4H, m,
CH2CH2), 3.45-3.60 (2H, m, 2× CHAHBN), 6.34 (1H, s, H-3), 7.68 (1H, dd, 1.2  and 8.4 Hz, H-6),
7.93 (1H, s, H-4), 8.01 (1H, d, J 8.4 Hz, H-7), 9.11 (2H, bs, NH2).
Indoles 49Aa-Hl.  Pd(PPh3)4 (15 mg, 4 mol%) was added to a flask containing 8 MiniKansTM each
containing a different resin-bound enol ether 47A-H (93 µeq./MiniKanTM), stirring with Cs2CO3
(1.21 g, 3.7 mmol), one of the aryl iodides a-h (3.7 mmol), and water (13.3 µL, 0.74 mmol) in
degassed DMF (30 mL) under argon. The suspension was shaken at 80 °C for 6 h.  The mixture was
allowed to cool and the MiniKansTM were separated from the reaction mixture and washed with 9:1
DMF-H2O (3×), alternately with MeOH and DCM (3×), and finally with MeOH and Et2O. The
MiniKansTM containing resin were then dried under vacuum.  This procedure was used for each of
the 12 different aryl iodides a-h and the resulting 96 MiniKansTM, each containing a different resin-
bound enol ether, were placed in an IRORI ClevapTM (automatic cleavage and evaporation) station,
so that each MiniKanTM was treated separately with trifluoroacetic acid (1%) in DCM for 1.5 h,
then with DCM-MeOH (4:1) for 0.5 h and the combined organics from each MiniKanTM were
collected separately and evaporated to give indoles 49Aa-Hl in the yields and purities shown in
Table 1.  Analysis of the library was by reversed phase HPLC/DAD-UV/ELSD/MS using a Waters
Analytical 4-way MUX QC System with an Agilent Zorbax SB C8, 21.2 x 250 mm column and
eluting with 0.1% trifluoroacetic acid in MeCN:H2O (4:1), Flow = 25 mL/min.  HPLC MS data is
displayed in Table 2 (library members in bold also have 1H NMR data for the reversed phase
HPLC-purified indoles as listed below).
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Table 2
HPLC retention times (min) for  indoles 49 (detected M+H+ in parenthesis)
A B C D E F G H
a 1.73
(440.2)
1.61
(378.2)
1.88
(454.2)
 1.44
(441.2)
1.73
(470.2)
1.49
(550.3)
2.00
(547.3)
*
b 5.30
(427.2 )
4.75
(365.2)
6.32
(441.2)
 1.42
(428.2)
5.33
(457.3)
3.93
(487.2)
7.46
(534.3)
*
c 7.22
(411.2 )
6.41
(349.2)
8.72
(425.2)
1.58
(412.2 )
7.23
(441.2)
5.17
(471.2)
5.24
(518.3)
*
d * * 6.03
(417.2)
1.40
(404.2)
5.14
(433.2 )
3.79
(463.2)
* *
e 4.90
(422.2 )
4.43
(360.2)
5.87
(436.2 )
1.35
(423.2)
4.92
(452.2)
3.66
(482.2)
6.86
(529.3 )
*
f 5.64
(403.1 )
1.44
(341.1)
6.78
(417.1 )
1.45
(404.2)
5.99
(443.2 )
4.19
(463.2 )
8.02
(510.3)
*
g 1.26
(387.1 )
* * * 3.83
(417.2)
1.52
(447.2)
2.06
(494.3)
*
h 4.34
(422.1)
3.93
(360.1)
5.15
(436.2)
1.33
(423.2)
4.40
(452.2)
3.35
(482.2)
5.92
(529.3)
1.45
(491.2)
i 3.89
(404.1)
3.46
(342.1 )
4.59
(418.2)
1.26
(405.1)
3.92
(434.2 )
2.98
(464.1)
* 1.48
(473.2)
j 8.57
(399.2)
7.55
(337.2)
11.52
(413.2)
1.49
(400.1 )
9.12
(429.2)
6.17
(459.2)
5.33
(506.3)
*
k 1.51
(412.2)
1.44
(350.2)
4.97
(426.2)
1.28
(413.2)
1.53
(442.2)
1.37
(472.2)
1.72
(519.3)
*
l 5.10
(399.2 )
4.50
(337.2)
6.36
(413.2)
1.30
(400.2)
5.22
(429.2 )
3.84
(459.2)
7.81
(506.3)
*
 * MW of product not detected
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N-Boc-5-(4'-methoxyphenyl)-2-(2"-phenylethyl)indole 49Ab.  Data as reported under indole 41
above.
N-Boc-5-(2'-methylphenyl)-2-(2"-phenylethyl)indole 49Ac.  δH (400 MHz, CDCl3): 1.70 (9H, s,
tBu),  2.28 (3H, s, CH3) 3.04 (2H, t, J 7.6 Hz, CH2Ph), 3.36 (2H, t, J 7.6 Hz, CH2CH2Ph), 6.39 (1H,
s, H-3), 7.20 (1H, dd, 2.0  and 8.8 Hz, H-6) 7.22-7.32 (9H, m, Ph, H-3' to H-6'), 7.38 (1H, d, J 2.0
Hz,  H-4), 8.09 (1H, d, J 8.8 Hz, H-7).
N-Boc-5-(3'-cyanophenyl)-2-(2"-phenylethyl)indole 49Ae. δH (400 MHz, CDCl3): 1.71 (9H, s,
tBu), 3.05 (2H, t, J 7.8 Hz, CH2Ph), 3.37 (2H, t, J 7.8 Hz, CH2CH2Ph), 6.41 (1H, s, H-3), 7.18-7.32
(5H, m, Ph) 7.44 (1H, dd, 2.0 and 8.8 Hz, H-6), 7.53 (1H, dt, J 0.4 and 7.6 Hz, H-5'), 7.59-7.63 (2H,
m, H-4 and H-6'), 7.86 (1H, ddd, J 1.2, 2.0 and 8.0 Hz, H-4'), 7.91-7.92 (1H, m, H-2'), 8.16 (1H, d,
J 8.8 Hz, H-7).
N-Boc-5-(4'-methoxyphenyl)-2-(3"-phenylpropyl)indole 49Cb. δH (400 MHz, CDCl3): 1.68 (9H,
s, tBu), 2.00-2.10 (2H, m, CH2CH2CH2) 2.75 (2H, t, J 7.6 Hz, CH2Ph), 3.06 (2H, t, J 7.6 Hz,
CH2CH2CH2Ph), 3.85 (3H, s, OCH3), 6.39 (1H, s, H-3), 6.98 (2H, d, J 8.8 Hz, H-3' and H-5'), 7.17-
7.32 (5H, m, Ph) 7.42 (1H, dd, 2.0 and 8.4 Hz, H-6), 7.56 (2H, d, J 8.8 Hz, H-2' and H-6'), 7.60
(1H, d, J 1.6 Hz, H-4), 8.11 (1H, d, J 8.4 Hz, H-7).
N-Boc-5-(4'-methoxyphenyl)-2-(3"-phenoxypropyl)indole 49Eb.  δH (400 MHz, CDCl3):  1.70
(9H, s, tBu), 2.21 (2H, tt, J 6.4 and 7.4 Hz, CH2CH2CH2), 3.23 (2H, t, J 7.4 Hz, CH2CH2CH2OPh),
3.85 (3H, s, OCH3) 4.06 (2H, t, J 6.4 Hz, CH2OPh), 6.42 (1H, s, H-3), 6.89-6.98 (3H, m, Ph), 7.00
(2H, d, J 2.8 Hz, H-3' and H-5') 7.26-7.30 (2H, m, Ph) 7.43 (1H, dd, 2.0 and 8.4 Hz, H-6), 7.54 (2H,
d, 8.8 Hz, H-2' and H-6'), 7.60 (1H, d, J 2.0 Hz, H-4), 8.10 (1H, d, J 8.4 Hz, H-7).
N-Boc-5-(2'-methylphenyl)-2-(3"-phenoxypropyl)indole 49Ec. δH (400 MHz, CDCl3): 1.70 (9H,
s, tBu), 2.22 (2H, tt, 6.2 and 7.4 Hz, CH2CH2CH2), 2.28 (3H, s, CH3) 3.24 (2H, t, J 7.4 Hz,
CH2CH2CH2OPh), 4.07 (2H, t, J 6.2 Hz, CH2OPh), 6.41 (1H, s, H-3), 6.90-6.96 (3H, m, Ph), 7.20
(1H, dd, 2.0 and 8.4 Hz, H-6), 7.22-7.26 (6H, m,  H-3' to H-6' and Ph ), 7.37 (1H, d, J 2.0 Hz, H-4),
8.10 (1H, d, J 8.4 Hz, H-7).
N-Boc-5-(3'-cyanophenyl)-2-(3"-phenoxypropyl)indole 49Ee. δH (400 MHz, CDCl3): 1.71 (9H, s,
tBu), 2.22 (2H, tt, J 6.2 and 7.4 Hz, CH2CH2CH2), 3.23 (2H, t, J 7.4 Hz, CH2CH2CH2OPh), 4.06
(2H, t, J 6.2 Hz, CH2OPh), 6.44 (1H, s, H-3), 6.89-6.96 (3H, m, Ph), 7.26-7.31 (2H, m, Ph) 7.43
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(1H, dd, J 2.0 and 8.8 Hz, H-6) 7.53 (1H, t, 7.6 Hz, H-5'), 7.59-7.63 (2H, m, H-4 and H-6'), 7.86
(1H, td, J 1.4 and 7.6 Hz, H-4'), 7.91 (1H, t, 1.6 Hz, H-2'), 8.17 (1H, d, J 8.8 Hz, H-7).
N-Boc-5-(2'-cyanophenyl)-2-(3"-phenoxypropyl)indole 49Eh. δH (400 MHz, CDCl3): 1.70 (9H,
s, tBu), 2.22 (2H, tt, J 6.2 and 7.4 Hz, CH2CH2CH2), 3.24 (2H, t, J 7.4 Hz, CH2CH2CH2), 4.06 (2H,
t, J 6.2 Hz, CH2CH2OPh), 6.45 (1H, s, H-3), 6.88-6.96 (3H, m, Ph), 7.26-7.31 (2H, m, Ph), 7.40-
7.44 (2H, m, H-4' and H-6), 7.55 (1H, dd, 0.8 and 7.6 Hz, H-6'), 7.61-7.66 (2H, m, H-4 and H-5'),
7.77 (1H, dd, J 2.0 and 8.0 Hz, H-3'), 8.18 (1H, d, J 8.8 Hz, H-7).
N-Boc-2-(3'-phenoxypropyl)-5-(pyrazin-2"-yl)-indole 49El. δH (400 MHz, CDCl3): 1.71 (9H, s,
tBu), 2.22 (2H, tt, J 6.2 and 7.4 Hz, CH2CH2CH2), 3.24 (2H, t, J 7.4 Hz, CH2CH2CH2), 4.07 (2H, t, J
6.2 Hz, CH2CH2OPh), 6.48 (1H, s, H-3), 6.89-6.97 (3H, m, Ph), 7.26-7.30 (2H, m, Ph) 7.90 (1H,
dd, 1.6 Hz and 8.8 Hz, H-6), 8.12 (1H, d, 1.6 Hz, H-4), 8.21 (1H, d, J 8.8 Hz, H-7), 8.47 (1H, d, J
2.4 Hz, H-6"), 8.62 (1H, dd, J 1.6 and 2.4 Hz, H-5"), 9.08 (1H, d, J 1.6 Hz, H-3").
N-Boc-2-[2'-(3",4"-dimethoxyphenyl)ethyl]-5-(4"'-methoxyphenyl)indole 49Fb.   δH (400 MHz,
CDCl3): 1.70 (9H, s, tBu), 2.97 (2H, t, J 7.8 Hz, CH2Ph), 3.33 (2H, t, J 7.8 Hz, CH2CH2Ph), 3.82
(3H, s, OCH3), 3.85 (3H, s, OCH3), 3.86 (3H, s, OCH3), 6.37 (1H, s, H-3),  6.73 (1H, d, J 1.6 Hz, H-
2"), 6.77-6.80 (2H, m, H-5" and H-6"), 6.98 (2H, d, J 8.8 Hz, H-3”' and H-5”'), 7.44 (1H, dd, 2.0
and 8.8 Hz, H-6), 7.55-7.60 (3H, m, H-4, H-2”' and H-6”'), 8.10 (1H, d, J 8.8 Hz, H-7).
N-Boc-2-[2'-(3",4"-dimethoxyphenyl)ethyl]-5-(2"'-methylphenyl)indole 49Fc.   δH (400 MHz,
CDCl3): 1.70 (9H, s, tBu), 2.29 (3H, s, ArCH3), 2.98 (2H, t, J 7.8 Hz, H-2'), 3.33 (2H, t, J 7.8 Hz, H-
1'), 3.82 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.37 (1H, s, H-3), 6.73 (1H, s, H-2"), 6.81 (2H, s, H-5"
and H-6", coincident), 7.20 (1H, dd, 2.0 and 8.8 Hz, H-6), 7.23-7.28 (4H, m, H-3”' to H-6”'), 7.37
(1H, d, J 2.0 Hz,  H-4), 8.09 (1H, d, J 8.8 Hz, H-7).
N-Boc-5-(3'-cyanophenyl)-2-[2"-(3"',4"'-dimethoxyphenyl)ethyl]indole 49Fe. δH (400 MHz,
CDCl3): 1.71 (9H, s, tBu), 2.98 (2H, t, J 7.6 Hz, H-2"), 3.34 (2H, t, J 7.6 Hz, H-1"), 3.82 (3H, s,
OCH3), 3.86 (3H, s, OCH3), 6.33 (1H, s, H-3), 6.73 (1H, d, J 1.6 Hz, H-2"'), 6.74-6.82 (2H, m, H-
5"' and H-6"'), 7.45 (1H, dd, 2.0 and 8.4 Hz, H-6), 7.52 (1H, dt, J 0.4 and 7.8 Hz, H-5'), 7.59-7.63
(2H, m, H-4 and H-6'), 7.86 (1H, td, J 1.6 and 8.0 Hz, H-4'), 7.91 (t, J 1.4 Hz, H-2'), 8.17 (1H, d, J
8.8 Hz, H-7).
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N-Boc-5-(2'-cyanophenyl)-2-[2"-(3"',4"'-dimethoxyphenyl)ethyl]indole 49Fh.  δH (400 MHz,
CDCl3):  1.71 (9H, s, tBu), 2.98 (2H, t, J 7.8 Hz, H-2"), 3.34 (2H, t, J 7.8 Hz, H-1"), 3.83 (3H, s,
OCH3), 3.86 (3H, s, OCH3), 6.42 (1H, s, H-3), 6.72-6.82 (3H, m, H-2"', H-5"' and H-6"'), 7.40-7.45
(2H, m, H-4' and H-6), 7.55 (1H, dd, 0.8 and 7.6 Hz, H-6'), 7.62-7.66 (2H, m, H-4 and H-5'), 7.77
(1H, dd, J 0.8 and 7.6 Hz, H-3'), 8.18 (1H, d, J 8.4 Hz, H-7).
N-Boc-2-[2'-(N-Boc-piperidin-4"-yl)ethyl]-5-(4"'-methoxyphenyl)indole 49Gb.   δH (400 MHz,
CDCl3): 1.06-1.25 (2H, m, piperidine), 1.46 (9H, s, tBu), 1.49-1.78 (5H, m, piperidine), 1.70 (9H, s,
tBu), 2.60-2.70 (2H, m, CH2CH2CH ), 3.05 (2H, t, J 7.6 Hz, H-1'), 3.86 (3H, s. OCH3), 4.05-4.20
(2H, m, 2× CHAHBN), 6.37 (1H, s, H-3), 6.99 (2H, d J 8.8 Hz, H-3”' and H-5”') 7.43 (1H, dd, 2.0
and 8.8 Hz, H-6), 7.55 (2H, d, J 8.8 Hz, H-2”' and H-6”'), 7.58 (1H, d, J 2.0 Hz, H-4), 8.08 (1H, d, J
8.8 Hz, H-7).
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